Oseltamivir effectiveness in seasonal influenza patients taking symptomatic therapy: Retrospective analysis of RCT data

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 12, 2013, Pages 932-941

  Toovey, Stephen ^a   Dutkowski, Regina ^b   Paul, Smith ^c   Smith, James R ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

^c Statistics for Research Ltd   (Switzerland)

Author keywords

Analgesics; Antibiotics; Oseltamivir; Over thecounter medication; Seasonal influenza

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTITUSSIVE AGENT; DECONGESTIVE AGENT; EXPECTORANT AGENT; NON PRESCRIPTION DRUG; OSELTAMIVIR; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; CHILL; COUGHING; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE OBSTRUCTION; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SEASONAL INFLUENZA; SELF MEDICATION; SLEEP QUALITY; SORE THROAT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; OSELTAMIVIR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84891331930     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201888     Document Type: Article

References (26)

1. Nicholson KG, Webster RG, Hay AJ. Textbook of influenza. Oxford: Blackwell Science Ltd.; 1998.
2. Biskupiak JE, Brixner DI, Howard K, Oderda GM. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Palliat Care Pharmacother. 2006; 20: 7-14. CrossRef PubMed
3. Moscona A . Neuraminidase inhibitors for influenza. N Engl J Med. 2005; 353: 1363-1373. CrossRef PubMed
4. Halloran ME, Hayden FG, Yang Y, Longini IM Jr, Monto AS. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol. 2007; 165: 212-221. CrossRef PubMed
5. Tamiflu PI. Tamiflu Prescribing Information. 2011. URL: http://www.gene.com/gene/products/information/tamiflu/pdf/pi.pdf., accessed 30 May 2012.
6. Tamiflu SmPC. Tamiflu Summary of Product Characteristics. 2011. URL: http://www.medicines.org. uk/emc/document.aspx?documentid=10446, accessed 30 May 2012.
7. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG; US Oral Neuraminidase Study Group. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA. 2000; 283: 1016-1024. CrossRef PubMed
8. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P; Neuraminidase Inhibitor Flu Treatment Investigator Group. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet. 2000; 355: 1845-1850. CrossRef PubMed
9. Singh S, Barghoorn J, Bagdonas A, Adler J, Treanor J, Kinnersley N, Ward P. Clinical benefits with oseltamivir in treating influenza in adult populations : results of a pooled and subgroup analysis. Clin Drug Investig. 2003; 23: 561-569. CrossRef PubMed
10. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003; 163: 1667-1672. CrossRef PubMed
11. Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis. 2011; 53: 277-279. CrossRef PubMed
12. Robson R, Saiedabadi N, Ward P. Oral oseltamivir reduces the duration of influenza illness by 2.7 days in previously healthy adults. Abstract presented at: the 9th International Congress on Infectious Diseases 10-13 April 2000, Buenos Aires, Argentina. Abstract 80.019.
13. Martin C, Mahoney P, Ward P. Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications. Int Congr Ser. 2001; 1219: 807-811. CrossRef
14. Treanor JJ. Reduction in the symptoms and complications of influenza A and B in patients treated with oseltamivir (the Time-to-Treat Study Group). Abstract presented at: the 38th Annual Meeting of the Infectious Diseases Society of America 7 - 10 September 2000, New Orleans, Louisiana, USA. Abstract 611.
15. Kaiser L, Fritz RS, Straus SE, Gubareva L, Hayden FG. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol. 2001; 64: 262-268. CrossRef PubMed
16. Kim YH, Kim JE, Hyun MC. Cytokine response in pediatric patients with pandemic influenza H1N1 2009 virus infection and pneumonia: comparison with pediatric pneumonia without H1N1 2009 infection. Pediatr Pulmonol. 2011; 46: 1233-1239. CrossRef PubMed
17. Wong ZX, Jones JE, Anderson GP, Gualano RC. Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung. Influenza Other Respir Viruses. 2011; 5: 343-350. CrossRef PubMed
18. Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, Wat C, Griffiths M, Waalberg E, Ward P; IMPACT Study Group. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003; 51: 123-129. CrossRef PubMed
19. Meier CR, Napalkov PN, Wegmüller Y, Jefferson T, Jick H . Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis. 2000; 19: 834-842. CrossRef PubMed
20. Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study. Curr Med Res Opin. 2007; 23: 2961-2970. CrossRef PubMed
21. Peters PH, Moscona A, Schulman KL, Barr CE. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. Medscape J Med. 2008; 10: 131 PubMed
22. Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics. 2008; 26: 911-924. CrossRef PubMed
23. Schoenbaum SC. Economic impact of influenza. The individual's perspective. Am J Med. 1987; 82 (6A): 26-30. CrossRef PubMed
24. Levy E. French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics. 1996; 9 (Suppl 3): 62-66. CrossRef PubMed
25. Sander B, Gyldmark M, Hayden FG, Morris J, Mueller E, Bergemann R. Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom. Eur J Health Econ. 2005; 6: 244-252. CrossRef PubMed
26. Vindt Holm M, Gyldmark M, Holme Hansen E. Pharmacoeconomic assessment of oseltamivir in treating influenza - the case of otherwise healthy Danish adolescents and adults. Pharm World Sci. 2004; 26: 339-345. CrossRef PubMed